Immunic Therapeutics

🧠 A closer look at progressive #MultipleSclerosis (#MS) Thank you to everyone who joined our Virtual Progressive MS R&D Day yesterday, and especially to our guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) for sharing their perspectives and valuable insights. The discussion explored key unmet needs in progressive MS (#PMS), ongoing research into MS progression, and the latest updates from #Immunic’s development program. ▶️ Missed the event? Watch the replay: bit.ly/48BRpw3 #MSResearch #Neurology #ProgressiveMS $IMUX

⏰ Starting today at 12:30 pm ET 🧠 Join #MultipleSclerosis (#MS) guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) alongside #Immunic's management team for our Virtual Progressive #MS (#PMS) R&D Day. 👉 Register: bit.ly/3VOFvMu #MultipleSclerosis #MSResearch #Neurology $IMUX #vidofludimus #IMU838

🧠 What We Learned at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026 🔊 Following #MSToronto2026, @Proactive_US spoke with our CMO Dr. Mike Panzara about key takeaways from this year’s meeting — including our presence at the congress as well as new multiple sclerosis (MS) clinical, biomarker, and preclinical data presented across four poster presentations. 👉 Watch the full interview here: bit.ly/4sDQogb @ACTRIMS @ECTRIMS #MSResearch #Neurology #Immunic $IMUX

🧠 Disability progression remains one of the greatest unmet needs in #MultipleSclerosis (#MS). 🔬This week, our management team will host a Virtual Progressive MS (#PMS) R&D Day featuring experts in MS research Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova). Don't miss the event on November 5 at 12:30 pm ET. The discussion will cover key unmet needs in PMS and the latest updates from our investigational development program. #MSResearch #Neurology #IMUX #Immunic

📢 Meet the #Immunic team at upcoming investor conferences this November 💼 November 9-11 @GuggenheimPtnrs 3rd Annual Healthcare Innovation Conference (#Boston): Fireside chat on November 9 at 1:00 pm ET and one-on-one investor meetings 🗽 November 10-12 @Stifel 2026 Healthcare Conference (#NewYork): Fireside chat on November 11 at 2:00 pm ET and one-on-one investor meetings 🇬🇧 November 17-18: One-on-one investor meetings in connection with @Jefferies Global Healthcare Conference (#London) Our team is looking forward to connecting with investors and peers throughout the month. 👉 More details: bit.ly/4sCVVUt $IMUX #InvestorRelations #Networking

🎃 The future should not be scary. 👻 For many people living with #MultipleSclerosis (#MS), uncertainty about what the future may hold is not a seasonal fright. It is a daily reality. That's why we are committed to advancing research aimed at helping people with MS look to the future with greater confidence, less uncertainty and more hope. Happy Halloween from the #Immunic team. 🧡

#MultipleSclerosis (#MS) is not a single biological story. Its biology has many layers. 🧬 Many things may shape each person’s experience of MS, including their genes, their environment, their resilience, progression beyond relapses, immune cell activity, and inflammation. At #Immunic, we listen first, then act on what patients, their families, and the physicians who treat them share. Our research on #Nurr1 and #DHODH explores different dimensions of the disease because deeper understanding is the first step toward improving everyday life of patients. #MSUncovered $IMUX

📅 Mark your calendar for our Progressive #MultipleSclerosis (#MS) R&D Day on November 5 🧠 Next week, members of #Immunic's management team will be joined by guest experts Jiwon Oh, MD, PhD, FRCPC (@UofT) and Maria Pia Sormani, PhD (@UniGenova) to discuss the key unmet needs in progressive MS (#PMS) and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with #neurodegeneration and MS progression. 🔎 Get all the details here: 6z11edl.s.gy/jahggI #MSResearch $IMUX #neurology #vidofludimus #IMU838

🔬 That’s a wrap on #MSToronto2026! It was a busy and rewarding congress for the #Immunic team last week, filled with scientific exchange, poster presentations and valuable conversations with colleagues and stakeholders from across the #MultipleSclerosis (#MS) community. 🎗️ We presented four posters, with particularly strong engagement during our two paper poster presentations. 🤝 Our booth was busy throughout the meeting, with many opportunities to connect and exchange perspectives at the 10th Joint @ACTRIMS-@ECTRIMS Meeting. Thank you to everyone who stopped by! $IMUX #Neurology #MSResearch

✨ Marking Jaa Roberson’s appointment as the new Chief People Officer of #Immunic, showcased on the #Nasdaq tower in New York City. 🏙️ Welcome again, Jaa, to team $IMUX! We are looking forward to our next phase of growth together. And thank you, @Nasdaq, for the continued support. #NasdaqListed #Leadership

🧠 In our #MSUncovered series, we take a closer look at biological processes relevant to #MultipleSclerosis (#MS). 🔬 One important area of research is #inflammation. In relapsing MS (#RMS), inflammation in specific areas of the brain and spinal cord involves activated immune cells, including T and B cells, and is associated with inflammatory disease activity. When highly active, these cells require large amounts of pyrimidines – essential building blocks that support their function and growth. #DHODH is a key enzyme in pyrimidine synthesis. Because DHODH supports this process in highly active immune cells, investigating DHODH inhibition is of interest as a way to regulate immune-cell activity associated with inflammation in relapsing MS. 🎗️ Each new discovery helps build a more complete picture of the disease and the challenges people living with MS continue to face. #Immunic $IMUX #MSResearch

🔬 Day 2 at #MSToronto2026. From scientific sessions and poster presentations to discussions with colleagues from across the #MultipleSclerosis (#MS) community, the meeting continues to provide valuable opportunities for learning, collaboration and scientific exchange. 🎥 Here are a few impressions from the 10th Joint @ACTRIMS-@ECTRIMS Meeting in Toronto 🇨🇦. 📍 Visit us at booth #516 to learn more about our investogational MS program. #Neurology $IMUX #Immunic #MSResearch

🧠 We are presenting new #MultipleSclerosis (#MS) clinical, biomarker, and preclinical data across four poster presentations at #MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. Together, the findings provide complementary clinical and mechanistic evidence supporting the differentiated profile of our lead asset across the MS spectrum, including favorable long-term disability signals in progressive MS and additional insight into the biology of disease progression.🎗️ 👉 Learn more: bit.ly/4zzLtiA @ACTRIMS @ECTRIMS #MSResearch #Neurology #Immunic $IMUX #vidofludimus #IMU838

🧠 Ahead of the 10th Joint #ACTRIMS-#ECTRIMS Meeting, our CEO Erik Lundgren joined @Proactive_US to discuss the evolving #MultipleSclerosis (#MS) landscape, $IMUX's poster presentations and what he is looking forward to at this year's meeting. 🎥 Watch the interview: bit.ly/47qh0Yv #MSToronto26 @ACTRIMS @ECTRIMS #Neurology #Immunic #MSResearch

🚀 Building a leading #MultipleSclerosis (#MS) organization requires exceptional science, strong execution and outstanding people. That's why we are pleased to welcome Jaa Roberson as #Immunic's new Chief People Officer. Jaa will play a key role in helping us attract, develop and retain the talent needed to support $IMUX's next stage of growth. 👏 👏 Please join us in welcoming Jaa to the team. Learn more: bit.ly/3UDO7VP

🔬 As #MSToronto2026 approaches, we are looking forward to sharing additional analyses from our #MultipleSclerosis (#MS) development program. Two of our abstracts explore important questions beyond traditional measures of disease activity: 🔹 Phase 2 #CALLIPER analyses examine the relationship between #EBV-related immune activity and cognitive performance in progressive MS (#PMS) 🔹 A new proposed disability endpoint evaluates capturing both disability worsening and improvement Together, these presentations reflect our continued efforts to better understand the factors that influence disability progression and patient outcomes in MS. 📍 Visit the #Immunic team at Booth #516. @ACTRIMS @ECTRIMS #MSResearch #Neurology $IMUX

#MultipleSclerosis (#MS) patients should not have to accept the status quo. 🧠 While today's therapies have helped transform the treatment landscape, important unmet needs remain. For many, symptoms and disability can continue to worsen despite largely controlled relapses and encouraging clinical measures. 🔬 That's why #Immunic remains focused on advancing understanding of progression and pursuing new ways to address the unmet needs that continue to affect people living with MS. Hear from our CEO Erik Lundgren on why we believe there is an opportunity to do better. #MSResearch #Neurology $IMUX